Noninvasive early detection of colorectal cancer by hypermethylation of the LINC00473 promoter in plasma cell-free DNA.

Autor: Ruiz-Bañobre J; Translational Medical Oncology Group (ONCOMET), Health Research Institute of Santiago de Compostela (IDIS), University Clinical Hospital of Santiago (CHUS/SERGAS), 15706, Santiago de Compostela, Spain.; Centro de Investigación Biomédica en Red Cáncer (CIBERONC), ISCIII, 28029, Madrid, Spain., Rodriguez-Casanova A; Cancer Epigenomics Laboratory, Epigenomics Unit, Translational Medical Oncology Group (ONCOMET), Health Research Institute of Santiago de Compostela (IDIS), University Clinical Hospital of Santiago (CHUS/SERGAS), 15706, Santiago de Compostela, Spain.; Roche-Chus Joint Unit, Translational Medical Oncology Group (ONCOMET), Health Research Institute of Santiago (IDIS), 15706, Santiago de Compostela, Spain.; Universidade de Santiago de Compostela (USC), 15782, Santiago de Compostela, Spain., Costa-Fraga N; Cancer Epigenomics Laboratory, Epigenomics Unit, Translational Medical Oncology Group (ONCOMET), Health Research Institute of Santiago de Compostela (IDIS), University Clinical Hospital of Santiago (CHUS/SERGAS), 15706, Santiago de Compostela, Spain.; Universidade de Santiago de Compostela (USC), 15782, Santiago de Compostela, Spain., Bao-Caamano A; Cancer Epigenomics Laboratory, Epigenomics Unit, Translational Medical Oncology Group (ONCOMET), Health Research Institute of Santiago de Compostela (IDIS), University Clinical Hospital of Santiago (CHUS/SERGAS), 15706, Santiago de Compostela, Spain.; Universidade de Santiago de Compostela (USC), 15782, Santiago de Compostela, Spain., Alvarez-Castro A; Department of Gastroenterology and Hepatology, University Clinical Hospital of Santiago (CHUS/SERGAS), 15706, Santiago de Compostela, Spain., Carreras-Presas M; Department of Gastroenterology and Hepatology, University Clinical Hospital of Santiago (CHUS/SERGAS), 15706, Santiago de Compostela, Spain., Brozos-Vazquez E; Translational Medical Oncology Group (ONCOMET), Health Research Institute of Santiago de Compostela (IDIS), University Clinical Hospital of Santiago (CHUS/SERGAS), 15706, Santiago de Compostela, Spain., Vidal-Insua Y; Translational Medical Oncology Group (ONCOMET), Health Research Institute of Santiago de Compostela (IDIS), University Clinical Hospital of Santiago (CHUS/SERGAS), 15706, Santiago de Compostela, Spain., Vazquez-Rivera F; Translational Medical Oncology Group (ONCOMET), Health Research Institute of Santiago de Compostela (IDIS), University Clinical Hospital of Santiago (CHUS/SERGAS), 15706, Santiago de Compostela, Spain., Candamio-Folgar S; Translational Medical Oncology Group (ONCOMET), Health Research Institute of Santiago de Compostela (IDIS), University Clinical Hospital of Santiago (CHUS/SERGAS), 15706, Santiago de Compostela, Spain.; Centro de Investigación Biomédica en Red Cáncer (CIBERONC), ISCIII, 28029, Madrid, Spain., Mosquera-Presedo M; Cancer Epigenomics Laboratory, Epigenomics Unit, Translational Medical Oncology Group (ONCOMET), Health Research Institute of Santiago de Compostela (IDIS), University Clinical Hospital of Santiago (CHUS/SERGAS), 15706, Santiago de Compostela, Spain.; Universidade de Santiago de Compostela (USC), 15782, Santiago de Compostela, Spain., Lago-Lestón RM; Liquid Biopsy Analysis Unit, Translational Medical Oncology Group (ONCOMET), Health Research Institute of Santiago de Compostela (IDIS), 15706, Santiago de Compostela, Spain., Muinelo-Romay L; Centro de Investigación Biomédica en Red Cáncer (CIBERONC), ISCIII, 28029, Madrid, Spain.; Liquid Biopsy Analysis Unit, Translational Medical Oncology Group (ONCOMET), Health Research Institute of Santiago de Compostela (IDIS), 15706, Santiago de Compostela, Spain., Vázquez-Bueno JÁ; Department of Pathology, Complejo Hospitalario Universitario de Ferrol (SERGAS), 15405, Ferrol, Spain., Sanz-Pamplona R; Unit of Biomarkers and Susceptibility, Oncology Data Analytics Program, Catalan Institute of Oncology (ICO), 08907, Barcelona, Spain.; Colorectal Cancer Group, Bellvitge Biomedical Research Institute (IDIBELL), 08907, Barcelona, Spain.; Biomedical Research Centre Network for Epidemiology and Public Health (CIBERESP), 28029, Madrid, Spain., Moreno V; Unit of Biomarkers and Susceptibility, Oncology Data Analytics Program, Catalan Institute of Oncology (ICO), 08907, Barcelona, Spain.; Colorectal Cancer Group, Bellvitge Biomedical Research Institute (IDIBELL), 08907, Barcelona, Spain.; Biomedical Research Centre Network for Epidemiology and Public Health (CIBERESP), 28029, Madrid, Spain.; Department of Clinical Sciences, Faculty of Medicine and Health Sciences, University of Barcelona, 08907, Barcelona, Spain., Goel A; Center for Gastrointestinal Research, Center for Translational Genomics and Oncology, Baylor Scott and White Research Institute, Charles A Sammons Cancer Center, Baylor University Medical Center, Dallas, TX, USA.; Department of Molecular Diagnostics and Experimental Therapeutics, Beckman Research Institute of City of Hope, Monrovia, CA, USA.; City of Hope Comprehensive Cancer Center, Duarte, CA, USA., Castillo L; Advanced Marker Discovery (AMADIX), 47004, Valladolid, Spain., Martin AC; Advanced Marker Discovery (AMADIX), 47004, Valladolid, Spain., Arroyo R; Advanced Marker Discovery (AMADIX), 47004, Valladolid, Spain., Esteller M; Centro de Investigación Biomédica en Red Cáncer (CIBERONC), ISCIII, 28029, Madrid, Spain.; Josep Carreras Leukaemia Research Institute (IJC), Barcelona, Spain.; Institucio Catalana de Recerca I Estudis Avançats (ICREA), Barcelona, Spain.; Physiological Sciences Department, School of Medicine and Health Sciences, University of Barcelona (UB), Barcelona, Spain., Crujeiras AB; Epigenomics in Endocrinology and Nutrition Group, Epigenomics Unit, Health Research Institute of Santiago de Compostela (IDIS), University Clinical Hospital of Santiago (CHUS/SERGAS), 15706, Santiago de Compostela, Spain.; Centro de Investigación Biomédica en Red Fisiopatología de La Obesidad y Nutrición (CIBERobn), ISCIII, 28029, Madrid, Spain., López-López R; Translational Medical Oncology Group (ONCOMET), Health Research Institute of Santiago de Compostela (IDIS), University Clinical Hospital of Santiago (CHUS/SERGAS), 15706, Santiago de Compostela, Spain. rafael.lopez.lopez@sergas.es.; Centro de Investigación Biomédica en Red Cáncer (CIBERONC), ISCIII, 28029, Madrid, Spain. rafael.lopez.lopez@sergas.es.; Roche-Chus Joint Unit, Translational Medical Oncology Group (ONCOMET), Health Research Institute of Santiago (IDIS), 15706, Santiago de Compostela, Spain. rafael.lopez.lopez@sergas.es., Díaz-Lagares A; Centro de Investigación Biomédica en Red Cáncer (CIBERONC), ISCIII, 28029, Madrid, Spain. angel.diaz.lagares@sergas.es.; Cancer Epigenomics Laboratory, Epigenomics Unit, Translational Medical Oncology Group (ONCOMET), Health Research Institute of Santiago de Compostela (IDIS), University Clinical Hospital of Santiago (CHUS/SERGAS), 15706, Santiago de Compostela, Spain. angel.diaz.lagares@sergas.es.

Publikováno v: Clinical epigenetics [Clin Epigenetics] 2022 Jul 09; Vol. 14 (1), pp. 86. Date of Electronic Publication: 2022 Jul 09.

Evaluation of a Targeted Next-Generation Sequencing Panel for the Non-Invasive Detection of Variants in Circulating DNA of Colorectal Cancer.

Autor: Rodríguez-Casanova A; Cancer Epigenomics, Translational Medical Oncology Group (Oncomet), Health Research Institute of Santiago (IDIS), University Clinical Hospital of Santiago (CHUS/SERGAS), 15706 Santiago de Compostela, Spain.; Translational Medical Oncology Group (Oncomet), Roche-Chus Joint Unit, Health Research Institute of Santiago (IDIS), 15706 Santiago de Compostela, Spain.; Universidade de Santiago de Compostela (USC), 15782 Santiago de Compostela, Spain., Bao-Caamano A; Cancer Epigenomics, Translational Medical Oncology Group (Oncomet), Health Research Institute of Santiago (IDIS), University Clinical Hospital of Santiago (CHUS/SERGAS), 15706 Santiago de Compostela, Spain.; Universidade de Santiago de Compostela (USC), 15782 Santiago de Compostela, Spain., Lago-Lestón RM; Translational Medical Oncology Group (Oncomet), Liquid Biopsy Analysis Unit, Health Research Institute of Santiago (IDIS), 15706 Santiago de Compostela, Spain., Brozos-Vázquez E; Translational Medical Oncology Group (Oncomet), Health Research Institute of Santiago (IDIS), University Clinical Hospital of Santiago (CHUS/SERGAS), 15706 Santiago de Compostela, Spain., Costa-Fraga N; Cancer Epigenomics, Translational Medical Oncology Group (Oncomet), Health Research Institute of Santiago (IDIS), University Clinical Hospital of Santiago (CHUS/SERGAS), 15706 Santiago de Compostela, Spain.; Universidade de Santiago de Compostela (USC), 15782 Santiago de Compostela, Spain., Ferreirós-Vidal I; Translational Medical Oncology Group (Oncomet), Liquid Biopsy Analysis Unit, Health Research Institute of Santiago (IDIS), 15706 Santiago de Compostela, Spain., Abdulkader I; Department of Pathology, University Clinical Hospital of Santiago (CHUS/SERGAS), 15706 Santiago de Compostela, Spain., Vidal-Insua Y; Translational Medical Oncology Group (Oncomet), Health Research Institute of Santiago (IDIS), University Clinical Hospital of Santiago (CHUS/SERGAS), 15706 Santiago de Compostela, Spain., Rivera FV; Translational Medical Oncology Group (Oncomet), Health Research Institute of Santiago (IDIS), University Clinical Hospital of Santiago (CHUS/SERGAS), 15706 Santiago de Compostela, Spain., Candamio Folgar S; Translational Medical Oncology Group (Oncomet), Health Research Institute of Santiago (IDIS), University Clinical Hospital of Santiago (CHUS/SERGAS), 15706 Santiago de Compostela, Spain.; Centro de Investigación Biomédica en Red Cáncer (CIBERONC), 28029 Madrid, Spain., López-López R; Translational Medical Oncology Group (Oncomet), Roche-Chus Joint Unit, Health Research Institute of Santiago (IDIS), 15706 Santiago de Compostela, Spain.; Translational Medical Oncology Group (Oncomet), Health Research Institute of Santiago (IDIS), University Clinical Hospital of Santiago (CHUS/SERGAS), 15706 Santiago de Compostela, Spain.; Centro de Investigación Biomédica en Red Cáncer (CIBERONC), 28029 Madrid, Spain., Muinelo-Romay L; Translational Medical Oncology Group (Oncomet), Liquid Biopsy Analysis Unit, Health Research Institute of Santiago (IDIS), 15706 Santiago de Compostela, Spain.; Centro de Investigación Biomédica en Red Cáncer (CIBERONC), 28029 Madrid, Spain., Diaz-Lagares A; Cancer Epigenomics, Translational Medical Oncology Group (Oncomet), Health Research Institute of Santiago (IDIS), University Clinical Hospital of Santiago (CHUS/SERGAS), 15706 Santiago de Compostela, Spain.; Centro de Investigación Biomédica en Red Cáncer (CIBERONC), 28029 Madrid, Spain.

Publikováno v: Journal of clinical medicine [J Clin Med] 2021 Sep 29; Vol. 10 (19). Date of Electronic Publication: 2021 Sep 29.

437P Designing clinical profiles that influence the discordance of RAS mutations in blood and tissue: Sidedness and anatomical metastasis as factors of disagreement

Autor: Brozos-Vázquez, E., Lago-Lestón, R., Covela-Rúa, M., De la Cámara-Gómez, J., Montes, A. Fernandez, Candamio-Folgar, S., Muinelo-Romay, L., Vidal-Insua, Y., Vázquez-Rivera, F., López-Rodríguez, R., Blanco-Freire, C., Ferreirós-Vidal, I., Lopez, R. Lopez

Publikováno v: In Annals of Oncology September 2020 31 Supplement 4:S427-S427

Circulating Tumor DNA (ctDNA) Dynamics Predict Early Response to Treatment in Metastasized Gastroesophageal Cancer (mGEC) After 2 Weeks of Systemic Treatment.

Autor: Tatalovic, Stefan^1,2,3 (AUTHOR) stefan.tatalovic@ordensklinikum.at, Doleschal, Bernhard⁴ (AUTHOR), Kupferthaler, Alexander^2,5 (AUTHOR), Grundner, Stephan⁵ (AUTHOR), Burghofer, Jonathan⁶ (AUTHOR), Webersinke, Gerald⁶ (AUTHOR), Schwendinger, Simon⁷ (AUTHOR), Jukic, Emina⁷ (AUTHOR), Zschocke, Johannes⁷ (AUTHOR), Danhel, Lorenz^1,3 (AUTHOR), Kirchweger, Antonia^1,3 (AUTHOR), Havranek, Lukas^1,3 (AUTHOR), Shalamberidze, Demetre^1,3 (AUTHOR), Rezaie, Daniel^1,3 (AUTHOR), Biebl, Matthias^1,2 (AUTHOR), Rumpold, Holger^2,4 (AUTHOR), Kirchweger, Patrick^1,2,3 (AUTHOR) patrick.kirchweger@ordensklinikum.at

Publikováno v: Cancers. Dec2024, Vol. 16 Issue 23, p3960. 14p.

P-157 - Efficacy and safety of FOLFIRI/Aflibercept (FA) in an elderly population with metastatic colorectal cancer (mCRC) after the failure of an oxaliplatin-based regimen

Autor: Martínez-Lago, N., Carmona Campos, M., Gonzalez Villarroel, P., Salgado Fernandez, M., De la Cámara Gómez, J., Romero Reinoso, C., Cousillas Castiñeiras, A., Méndez Méndez, J., Vidal Insua, Y., Reboredo Rendo, C., Covela Rúa, M., Quintero Aldana, G., Graña Suarez, B., Carral Maseda, A., Jorge Fernandez, M., Pellón Augusto, M., Grande Ventura, C., Gallardo Martin, E., Fernández Montes, A., Reboredo-Lopez, M.

Publikováno v: In Annals of Oncology July 2019 30 Supplement 4:iv42-iv43